Physician profile
David Russell
NPI 1801845862
$1,619.60
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $182 · 2021: $257 · 2022: $624 · 2023: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $547.19 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Avion Pharmaceuticals | $233.49 | 2021-2023 | Balcoltra |
| Pfizer INC. | $173.22 | 2019-2023 | |
| Astellas Pharma US INC | $171.15 | 2019-2023 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $126.13 | 2021-2023 | |
| Urovant Sciences INC | $100.64 | 2022 | |
| Therapeuticsmd, INC. | $61.20 | 2019-2022 | |
| Novo Nordisk INC | $49.58 | 2022-2023 | Wegovy |
| Allergan, INC. | $39.89 | 2019-2020 | |
| Evofem Biosciences, INC. | $30.91 | 2021 | |
| Becton, Dickinson and Company | $24.34 | 2020 | |
| Myovant Sciences INC. | $19.28 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.44 | 2022 | |
| Roche Diagnostics Corporation | $13.73 | 2019 | |
| Hologic Sales and Service, LLC | $11.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.